Literature DB >> 28249983

Does osteofibrous dysplasia progress to adamantinoma and how should they be treated?

D W Scholfield1, Z Sadozai1, C Ghali1, V Sumathi1, H Douis1, L Gaston1, R J Grimer1, L Jeys1.   

Abstract

AIMS: The aim of this study was to identify any progression between benign osteofibrous dysplasia (OFD), OFD-like adamantinoma and malignant adamantinoma, and to investigate the rates of local recurrence, metastases and survival, in order to develop treatment algorithms for each. PATIENTS AND METHODS: A single institution retrospective review of all patients presenting with OFD, OFD-like adamantinoma and adamantinoma between 1973 and 2012 was undertaken. Complete data were available for 73 patients (42 with OFD; ten with an OFD-like adamantinoma and 21 with an adamantinoma). The mean follow-up was 10.3 years (3 to 25) for OFD, 9.2 years (3.0 to 26.3) for OFD-like and 11.6 years (0.25 to 33) for adamantinoma.
RESULTS: The mean age at diagnosis for OFD was 13.5 years (1 to 49), 10.5 years (6 to 28) for OFD-like and 34 years (14 to 86) for adamantinoma. A total of 24 of the 42 patients with OFD (57%) have not required any treatment and have been managed with observation. A total of 18 of the 42 patients with OFD underwent surgery, 13 with curettage and five with resection. In all, three patients developed recurrence following curettage (23%) but none following resection. All these patients were cured with further limited surgery. A total of six patients initially diagnosed with OFD were subsequently found to have OFD-like adamantinoma. Of the ten patients initially diagnosed with OFD-like adamantinoma, three (30%) were managed with observation alone and seven underwent surgery, two with curettage and five with resection. Local recurrence arose in two patients, one each after curettage and resection. No patients with either OFD or an OFD-like adamantinoma developed metastases or had progression to adamantinoma. All patients with an adamantinoma were treated by surgery, three with curettage, six with amputation and 12 with excision. In all, two of the three treated with curettage developed local recurrence, requiring further surgery. Late development of both local recurrence and metastases led to a ten year disease specific survival of 93% which had dropped to 39% by 20 years.
CONCLUSION: We found no evidence of progression from OFD to adamantinoma. Conservative management with observation or curettage is often successful for patients with OFD and OFD-like adamantinoma. Resection with clear margins is required for patients with adamantinoma. Late tumour recurrence is not uncommon in adamantinoma and prolonged follow-up should be considered. Cite this article: Bone Joint J 2017;99-B:409-16. ©2017 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Adamantinoma; Osteofibrous dysplasia; Osteofibrous dysplasia -like adamantinoma

Mesh:

Year:  2017        PMID: 28249983     DOI: 10.1302/0301-620X.99B3.38050

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  9 in total

Review 1.  Sclerotic bone lesions caused by non-infectious and non-neoplastic diseases: a review of the imaging and clinicopathologic findings.

Authors:  Vaibhav Gulati; Majid Chalian; Jaehyuck Yi; Uma Thakur; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2020-10-11       Impact factor: 2.199

Review 2.  The 2020 World Health Organization classification of bone tumors: what radiologists should know.

Authors:  Sinchun Hwang; Meera Hameed; Mark Kransdorf
Journal:  Skeletal Radiol       Date:  2022-07-19       Impact factor: 2.128

3.  Osteofibrous dysplasia-like adamantinoma of isolated fibula in a child mimicking chronic osteomyelitis with pathological fracture.

Authors:  Pierre-Emmanuel Goetz; Dana Dumitriu; Christine Galant; Pierre-Louis Docquier
Journal:  J Surg Case Rep       Date:  2022-06-07

4.  Adamantinomatous tumors: Long-term follow-up study of 20 patients treated at a single institution.

Authors:  Eugenia Schwarzkopf; Yoely Tavarez; John H Healey; Meera Hameed; Daniel E Prince
Journal:  J Surg Oncol       Date:  2020-04-25       Impact factor: 3.454

5.  Rapidly Progressive Classic Adamantinoma of the Spine: Case Report and Literature Review.

Authors:  Yan Lou; Ying Li; Lei Xu; Xiaoping Jing; Su Chen; Minglei Yang; Hongyu Jiang; Chenglong Zhao; Haifeng Wei; Jianru Xiao
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

6.  Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis.

Authors:  Mahmut Nedim Aytekin; Recep Öztürk; Kamil Amer
Journal:  J Oncol       Date:  2020-06-16       Impact factor: 4.375

7.  TIBIAL ADAMANTINOMA: ANALYSIS OF SEVEN CONSECUTIVE CASES IN A SINGLE INSTITUTION.

Authors:  Juan Pablo Zumárraga; Ricardo Cartolano; Marcelo Tomio Kohara; André Mathias Baptista; Felipe Gonçalves Dos Santos; Olavo Pires de Camargo
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

8.  Outcome of osteofibrous dysplasia-like versus classic adamantinoma of long bones: a single-institution experience.

Authors:  Zhiping Deng; Lihua Gong; Qing Zhang; Lin Hao; Yi Ding; Xiaohui Niu
Journal:  J Orthop Surg Res       Date:  2020-07-16       Impact factor: 2.359

9.  Osteofibrous dysplasia-like adamantinoma treated via intercalary segmental resection with partial cortex preservation using pedicled vascularized fibula graft: a case report.

Authors:  Yuji Yamamura; Makoto Emori; Nobuyuki Takahashi; Mitsumasa Chiba; Junya Shimizu; Yasutaka Murahashi; Shintaro Sugita; Kousuke Iba; Tadashi Hasegawa; Toshihiko Yamashita
Journal:  World J Surg Oncol       Date:  2020-08-13       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.